Invivyd Q3 2024 net product revenue $9.3M but net loss widens to $60.7M; cash $106.9M

Invivyd, Inc.

2024-Q3 EPS reported -$1.28 revenue$11,564,000

PEMGARDA net product revenue $9.3M, up from $2.3M in Q2 2024; not at previously anticipated rates.
Net loss $60.7M ($0.51 EPS) vs $39.4M ($0.36 EPS) in Q3 2023; R&D spending rose to $57.9M.
Cash and equivalents $106.9M; year-end 2024 cash expected at least $65M, targeting near-term profitability.
NEJM published Invivyd letter on PEMGARDA immunobridging pathway; Ho Lab letter with conflicting in vitro data published same day.
VYD2311 Phase 1 dosing began August 2024; preliminary data readout expected late Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.